The colorectal team is composed of laboratory and population scientists working closely with clinicians to provide the most targeted therapies and prognostics tools available.
This is a highly interdisciplinary team of experts at Fred Hutchinson Cancer Research Center and UW Medicine which have identified key factors that affect a person’s colorectal risk. We are investigating tests that could dramatically improve colorectal cancer screening and are leading the first study to determine the factors that determine outcome after a colorectal cancer diagnosis.
We have a diverse team for the management of colorectal cancer patients. Studies have shown that the first treatment you receive for cancer is by far the most important. On average, colon cancer patients who begin their treatment with us have better survival rates than those who started treatment elsewhere. The GI Cancer Prevention Program Clinic at Seattle Cancer Care Alliance is the only clinic in Northwest offering comprehensive care for hereditary GI cancer syndromes.
The colorectal research team is made up of investigators and clinicians who are dedicated to better understanding the causes and risks for colorectal cancer. Research in basic science, genetics, clinical medicine, cancer prevention, and epidemiology at Fred Hutchinson Cancer Research Center and the University of Washington has resulted in treatment options that include surgery, chemotherapy and targeted therapies.
Our researchers lead in the development of cutting edge biomarkers for early detection and risk prediction for colorectal cancer. Population based scientists at Fred Hutch have developed research programs funded by the National Institutes of Health to identify novel prognostic factors for colorectal cancer.
Dr. Grady’s clinical focus is on the management of gastrointestinal cancer familial syndromes, colon cancer prevention, and Barrett’s Esophagus. His research focuses on the molecular and cell biology of gastrointestinal cancer, genetic and epigenetic alterations in cancer, cancer biomarkers and hereditary cancer syndromes.